140 related articles for article (PubMed ID: 36143168)
1. Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.
Pierre-François MJD; Gagné V; Brukner I; Krajinovic M
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143168
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
4. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
5. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
[TBL] [Abstract][Full Text] [Related]
6. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
[TBL] [Abstract][Full Text] [Related]
7. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.
Sychev DA; Denisenko NP; Sizova ZM; Grachev AV; Velikolug KA
Pharmgenomics Pers Med; 2015; 8():111-4. PubMed ID: 26109874
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Shoji K; Hikino K; Saito J; Matsui T; Utano T; Takebayashi A; Tomizawa D; Kato M; Matsumoto K; Ishikawa T; Kawai T; Nakamura H; Miyairi I; Terao C; Mushiroda T
J Infect Chemother; 2024 Jun; ():. PubMed ID: 38897411
[TBL] [Abstract][Full Text] [Related]
10. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
González A; Moniche F; Cayuela A; García-Lozano JR; Torrecillas F; Escudero-Martínez I; Gonzalez-Marcos JR; Mayol A; Montaner J
Eur J Vasc Endovasc Surg; 2016 Feb; 51(2):175-86. PubMed ID: 26526111
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.
Sukasem C; Tunthong R; Chamnanphon M; Santon S; Jantararoungtong T; Koomdee N; Prommas S; Puangpetch A; Vathesatogkit P
Pharmgenomics Pers Med; 2013; 6():85-91. PubMed ID: 24019752
[TBL] [Abstract][Full Text] [Related]
13. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N; V S; V V RK; H V V M; M S; Banerjee R; Tandan M; D NR
Meta Gene; 2016 Sep; 9():159-64. PubMed ID: 27419077
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
15. Combined Effect of
Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
[TBL] [Abstract][Full Text] [Related]
16. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
Du YX; Zhu YX; Li L; Yang J; Chen XP
Pharmacogenet Genomics; 2024 May; ():. PubMed ID: 38747453
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
[TBL] [Abstract][Full Text] [Related]
18. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
19. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
20. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
